Measles rubella vaccine

The measles rubella vaccine is a combination vaccine that provides active immunization against both measles and rubella viruses. It is most commonly administered as part of the MMR (measles, mumps, and rubella) or MR (measles-rubella) vaccines. The primary mechanism of action involves stimulating the immune system to produce antibodies against live attenuated strains of the measles and rubella viruses, thereby conferring immunity without causing disease. The main indication for this vaccine is the prevention of measles and rubella infections in children and adults. The first dose is typically given at 12–15 months of age with a second dose at 4–6 years[1][2][5]. Developers include academic institutions such as The Wistar Institute for the original virus strains[6], while manufacturing is carried out by various pharmaceutical companies worldwide.

Brand names

MR-VACEravaxBiovac MR

Other names

MMRMMR vaccinemeasles mumps rubella vaccine